Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

被引：66

作者：

Roussou, Maria ^{[1
]}

Kastritis, Efstathios ^{[1
]}

Christoulas, Dimitrios ^{[1
]}

Migkou, Magdalini ^{[1
]}

Gavriatopoulou, Maria ^{[1
]}

Grapsa, Irini ^{[1
]}

Psimenou, Erasmia ^{[1
]}

Gika, Dimitra ^{[1
]}

Terpos, Evangelos ^{[1
]}

Dimopoulos, Meletios A. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 11528, Greece

来源：

LEUKEMIA RESEARCH | 2010年 / 34卷 / 10期

关键词：

Multiple myeloma; Renal impairment; Bortezomib; Thalidomide; Lenalidomide; Conventional chemotherapy; BORTEZOMIB; IMPAIRMENT; SURVIVAL; REGIMENS;

D O I：

10.1016/j.leukres.2010.04.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The purpose of this analysis was to assess the effect of novel agent-based regimens on the improvement of renal impairment (RI) in newly diagnosed patients with multiple myeloma. Ninety-six consecutive patients with RI received conventional chemotherapy (CC)-based regimens (n = 32), IMiDs-based regimens (n = 47) or bortezomib-based regimens (n = 17) as frontline therapy. Improvement of RI was more frequent in patients treated with novel agents (79% in IMiD- and 94% in bortezomib-treated groups versus 59% in CC-treated group; p = 0.02). Bortezomib-based regimens and CrCl > 30 ml/min at baseline independently correlated with a higher probability of at least renal partial response (PRrenal) and with a shorter time to PRrenal or better. Thus bortezomib-based regimens may be the preferred treatment for newly diagnosed myeloma patients with RI. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：1395 / 1397

页数：3

共 8 条

[1] VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study [J].

Dimopoulos, Meletios A. ;

Richardson, Paul G. ;

Schlag, Rudolf ;

Khuageva, Nuriet K. ;

Shpilberg, Ofer ;

Kastritis, Efstathios ;

Kropff, Martin ;

Petrucci, Maria T. ;

Delforge, Michel ;

Alexeeva, Julia ;

Schots, Rik ;

Masszi, Tamas ;

Mateos, Maria-Victoria ;

Deraedt, William ;

Liu, Kevin ;

Cakana, Andrew ;

van de Velde, Helgi ;

Miguel, Jesus F. San .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6086-6093

[2] Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors [J].

Dimopoulos, Meletios A. ;

Roussou, Maria ;

Gavriatopoulou, Maria ;

Zagouri, Flora ;

Migkou, Magdalini ;

Matsouka, Charis ;

Barbarousi, Despina ;

Christoulas, Dimitrios ;

Primenou, Erasmia ;

Grapsa, Irini ;

Terpos, Evangelos ;

Kastritis, Efstathios .

CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (04) :302-306

[3]

Herrera Guillermo A., 2007, V153, P105

[4] Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents [J].

Kastritis, Efstathios ;

Anagnostopoulos, Athanasios ;

Roussou, Maria ;

Gika, Dimitra ;

Matsouka, Charis ;

Barmparousi, Despina ;

Grapsa, Irini ;

Psimenou, Erasmia ;

Bamias, Aristotle ;

Dimopoulos, Meletios Athanasios .

HAEMATOLOGICA, 2007, 92 (04) :546-549

[5] Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study [J].

San-Miguel, J. F. ;

Richardson, P. G. ;

Sonneveld, P. ;

Schuster, M. W. ;

Irwin, D. ;

Stadtmauer, E. A. ;

Facon, T. ;

Harousseau, J-L ;

Ben-Yehuda, D. ;

Lonial, S. ;

Goldschmidt, H. ;

Reece, D. ;

Blade, J. ;

Boccadoro, M. ;

Cavenagh, J. D. ;

Neuwirth, R. ;

Boral, A. L. ;

Esseltine, D-L ;

Anderson, K. C. .

LEUKEMIA, 2008, 22 (04) :842-849

[6] Bortezomib-Induced Survival Signals and Genes in Human Proximal Tubular Cells [J].

Sarkoezi, Rita ;

Perco, Paul ;

Hochegger, Kathrin ;

Enrich, Julia ;

Wiesinger, Martin ;

Pirklbauer, Markus ;

Eder, Susanne ;

Rudnicki, Michael ;

Rosenkranz, Alexander R. ;

Mayer, Bernd ;

Mayer, Gert ;

Schramek, Herbert .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (03) :645-656

[7] Management of Complications in Multiple Myeloma [J].

Terpos, Evangelos ;

Cibeira, M. Teresa ;

Blade, Joan ;

Ludwig, Heinz .

SEMINARS IN HEMATOLOGY, 2009, 46 (02) :176-189

[8] Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration [J].

Terpos, Evangelos ;

Katodritou, Eirini ;

Tsiftsakis, Evangelos ;

Kastritis, Efstathios ;

Christoulas, Dirnitrios ;

Pouli, Anastasia ;

Michalis, Eurydiki ;

Verrou, Evgenia ;

Anargyrou, Konstantinos ;

Tsionos, Konstantinos ;

Dimopoulos, Meletios A. ;

Zervas, Konstantinos .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (03) :372-379

← 1 →